Porphysome nanoparticles for imaging advanced gynecological cancers
Part of Cancer, Women’s health & pregnancy clinical trials.
This early-phase trial tests a new imaging agent called Porphysome nanoparticles to see if it can help doctors see gynecological cancers more clearly on scans. It's for women with advanced cancer that cannot be cured, and who are already receiving standard treatments like chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older.
- Your cancer is advanced (has spread) and is a type of gynecological cancer, like ovarian, uterine, or cervical cancer.
- You are not receiving treatment meant to cure your cancer—only treatments to control it.
- You can lie still for at least 20 minutes and are not claustrophobic.
- You have not had a nuclear medicine scan (like a PET scan) for other reasons during the study period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new PET scan tracer that targets a protein found on certain cancer cells. It may help doctors better see and understand tumors in people with colorectal, gastric, pancreatic, lobular breast, or ovarian cancer.
This study uses a new imaging tracer, called 68Ga-SorB, during a PET/CT scan to look at tumors. It may help doctors see cancer more clearly. The trial is for adults with certain types of solid tumors (such as melanoma, liver, lung, breast, pancreatic, ovarian, or bile duct cancer) who need a PET/CT scan as part of their care.
This trial tests a special imaging technique that may help doctors see and stage solid tumors more precisely. It uses a targeted radioactive tracer to highlight cancer cells during PET and SPECT scans, which could help plan better treatment.
This study tests a new way of taking pictures of tumors (metastases) using an upgraded gamma camera. The goal is to see if this new method produces clearer images, which could help doctors find and treat cancer better. Participation is only for people who are already having a bone scan or a scan after certain types of radiation therapy.
This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.
This trial evaluates a new radioactive tracer that targets a protein called EpCAM found on many solid tumors. It aims to improve PET/CT scans for diagnosing and staging cancer. Participants will receive the tracer before their scheduled biopsy or surgery.
Hear when a new Gynecological Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.